Filing Flows › Nurix Therapeutics (NRIX) › Q3 FY25
Nurix Therapeutics (NRIX) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Oct 9, 2025
Nurix Therapeutics (NRIX) reported revenue of $7.9M for the third quarter fiscal 2025 (Q3 FY25), -37% from a year earlier and -82% from the quarter before.
Nurix Therapeutics, Q3 FY25: revenue $7.9M (-37% year over year), net loss $86.4M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.9M | -82% | -37% |
| Operating profit | −$91.4M | — | — |
| Net earnings | −$86.4M | — | — |
| Operating cash flow | −$57.4M | — | — |
What changed
Revenue was $7.9M in Q3 FY25, down 37% year over year and down 82% from the previous quarter.
Operating costs exceeded revenue by $91.4M, an operating margin of -1157.7%. Total costs grew 48% against a revenue fall of 37%. The fastest-growing cost line was Research & development (+55%). The quarter ended with a net loss of $86.4M, wider than the previous quarter's $43.5M loss.
Operating cash flow was −$57.4M. Non-cash charges added back $2.0M of depreciation and amortization and $9.8M of share-based compensation. Working capital and other items added $17.2M. Capital expenditures of $2.7M exceeded it, leaving free cash flow of −$60.1M.
Questions
What was Nurix Therapeutics' revenue in the third quarter fiscal 2025?
Nurix Therapeutics (NRIX) reported revenue of $7.9M for the third quarter fiscal 2025 (Q3 FY25), -37% from a year earlier and -82% from the quarter before.
Source: Nurix Therapeutics 10-Q on SEC EDGAR.